何茂洲

2023年03月02日 09:18    药学院    点击:[]


 


 

个人信息:

何茂洲 博士

副研究员,国科大杭州高等研究院

浙江省杭州市西湖区象山支路11号楼3B-313 310012 

Email:hemaozhou@ucas.ac.cn 


教育背景

2014.09-2020.08   厦门大学   理学博士 (导师:李少伟教授,夏宁邵院士)

2009.09-2014.07   南昌大学   医学学士


工作经历:

2023.03~现在  国科大杭州高等研究院 副研究员

2022.09-2023.03 国科大杭州高等研究院 助理研究员

2020.09-2022.09 西湖大学    博士后 (合作导师:于洪涛教授)


研究方向:

  1. GPCR动态调控的分子机理研究,GPCR相关药物开发(如抗体等)。

  2. 人类大分子机器的结构与功能研究。

  3. 病毒与宿主相互作用的分子机制研究。

代表性研究成果

近五年在国际权威期刊共发表SCI论文20篇,其中第一作者或通讯作者(含共同)9篇,分别发表在 Cell Host & MicrobeNature MicrobiologyNature CommunicationsPNASnpj VaccinesJournal of Virology Protein & Cell等权威期刊 (# co-first author, * corresponding author)

 

  1. 1. Shi, J., Zhao, X.#*, Jin X., Li J., Liu Y., Liu H., … He M., *, Sun L.*, Wang P.*, Chu H* (2025). Pathogenicity, virological features, and immune evasion of SARS-CoV-2 JN.1-derived variants including JN.1.7, KP.2, KP.3, and KP.3.1.1.” Nature Communications, 2025 (Accepted)

  2. 2. Lin, X., L. Zhao, H. Cai, X. Chang, Y. Tang, T. Luo, M. Wu, C. Yi, L. Ma, X. Chu, S. Han, Q. Zhao*, B. Wu*, M. He* and Y. Zhu* (2025). "Structural insights into the distinct ligand recognition and signaling of the chemerin receptors CMKLR1 and GPR1." Protein & Cell 16(5): 381-385.

  3. 3. He, M.#, Xu, L.#, Zheng, Q.#, Zhu, R.#, Yin, Z.#, Zha, Z., Lin, Y., Yang, L., Huang, Y., Ye, X., Li, S., Hou, W., Wu, Y., Han, J., Liu, D., Li, Z., Chen, Z., Yu, H., Que, Y., Wang, Y., Yan, X., Zhang, J., Gu, Y., Hong, Z.*, Cheng, T.*, Li, S.*, Xia N.*, Identification of Antibodies with Non-overlapping Neutralization Sites that Target Coxsackievirus A16, Cell Host & Microbe, 2020, 27(2): 249-261; (细胞出版社Cell Press 2020中国年度论文)

  4. 4. He, M.#, X. Chi#, Z. Zha#, Y. Li, J. Chen, Y. Huang, S. Huang, M. Yu, Z. Wang, S. Song, X. Liu, S. Wei, Z. Li, T. Li, Y. Wang, H. Yu, Q. Zhao, J. Zhang, Zheng, Q.*, Gu, Y.*, Li, S.*, Xia N.*, Structural basis for the shared neutralization mechanism of three classes of human papillomavirus type 58 antibodies with disparate modes of binding, Journal of Virology, 2021, 95(7): e01587-20;

  5. 5. Zheng, Q.#, Zhu, R.#, Xu, L.#, He, M.#, Yan, X.#, Liu, D., Yin, Z., Wu, Y., Li, Y., Yang, L., Hou, W., Li, S., Li, Z., Chen, Z., Li, Z., Yu, H., Gu, Y., Zhang, J., Baker T S., Hong Z., Graham Barney S.*, Cheng, T.*, Li, S.*, Xia, N.*,  Atomic structures of enterovirus D68 in complex with two monoclonal antibodies define distinct mechanisms of viral neutralization, Nature Microbiology, 2019, 4(1): 124-133;

  6. 6. Li, Z.#, Song, S.#, He, M.#, Wang, D., Shi, J., Liu, X., Li, Y., Chi, X., Wei, S., Yang, Y., Wang, Z., Li J., Qian H., Yu H., Zheng Q., Yan X., Zhao Q., Zhang J., Gu Y.*, Li S.*, Xia N*. Rational design of a triple-type human papillomavirus vaccine by compromising viral-type specificity, Nature Communications, 2018, 9(1): 5360;

  7. 7. Zheng Q#, Jiang J#, He M#, Zheng Z#, Yu H, Li T, Xue W, Tang Z, Ying D, Li Z, Song S, Liu X, Wang K, Zhang Z, Wang D, Wang Y, Yan X, Zhao Q, Zhang J, Gu Y.*, Li S.*, Xia N.*. Viral neutralization by antibody-imposed physical disruption, Proceedings of the National Academy of Sciences of the United States of America, 2019, 116(52): 26933-40;

  8. 8. Huang W#, He M#, Ning T#, Nie J, Zhang F, Zheng Q, Zhang R, Xu Y, Gu Y, Li S*, Wang Y*. Structural characterization of a neutralizing mAb H16.001, a potent candidate for a common potency assay for various HPV16 VLPs, npj Vaccines, 2020, 5:0-89;

  9. 9. Zhang, Z.#, He, M.#, Bai, S.#, Zhang, F., Jiang, J., Zheng, Q., Gao, S., Yan, X., Li, S.*, Gu, Y.*, Xia, N., Vriuses, 2018, 10(12):0-667;

  10. 10. Lu P#, Liu Y#, He M, Cao T, Yang M, Qi S, Yu H*, Gao H*., Cryo-EM structure of human O-GlcNAcylation enzyme pair OGT-OGA complex. Nature Communications. 2023;14(1):6952.

  11. 11. Zheng Q,# Zhu R,# Yin Z#, Xu L#, Sun H,# Yu H#, Wu Y, Jiang Y, Huang Q, Huang Y, Zhang D, Liu L, Yang H, He, M, Zhou Z, Jiang Y, Chen Z, Zhao H, Que Y, Kong Z, Zhou L, Li T, Zhang J, Luo W, Gu Y*,Cheng T*, Li S*, Xia N*., Structural basis for the synergistic neutralization of coxsackievirus B1 by a triple-antibody cocktail. Cell Host & Microbe. 2022;30(9):1279-94.e6.

  12. 12. Wang G#, Zha Z#, Huang P#, Sun H#, Huang Y, He M, Chen T, Lin L, Chen Z, Kong Z, Que Y, Li T, Gu Y, Yu H, Zhang J, Zheng Q*, Chen Y*, Li S*, Xia N*. Structures of pseudorabies virus capsids. 2022, Nature Communications 13:1533;

  13. 13. Xu L#, Zheng Q#, Zhu R#, Yin Z#, Yu H#, Lin Y, Wu Y, He M, Huang Y, Jiang Y, Sun H, Zha Z, Yang H, Huang Q, Zhang D, Chen Z, Ye X, Han J, Yang L, Liu C, Que Y, Fang M, Gu Y, Zhang J, Luo W, Zhou ZH*, Li S*, Cheng T*, Xia N*, Cryo-EM structures reveal the molecular basis of receptor-initiated coxsackievirus uncoating, Cell Host & Microbe, 2021, 29:448-462.e5;

  14. 14. Wang W#, Zheng Q#, Pan D#, Yu H#, Fu W, Liu J, He M, Zhu R, Cai Y, Huang Y, Zha Z, Chen Z, Ye X, Han J, Que Y, Wu T, Zhang J, Li S*, Zhu H*, Zhou ZH*, Cheng T*, Xia N*, Near-atomic cryo-electron microscopy structures of varicella-zoster virus capsids, Nature Microbiology, 2020, 5(12):1542-1552;


科研项目:


1. 中国博士后创新人才支持计划,项目负责人;

2. 国家自然科学基金青年项目,趋化素受体GPR1CMKLR1调控beta-arrestin1信号通路的结构和功能研究,项目负责人;

3. 浙江省博士后科研项目择优资助一等资助, 项目负责人;

4. 浙江省自然科学基金-探索青年项目,项目负责人;

5. 浙江省自然科学基金-重大项目,胰高血糖素受体信号转导过程的动态调控机制研究,骨干;

6. 国家自然科学基金重点项目,人源黏连蛋白动态过程与调控机制,骨干;

7. 国家自然科学基金重大项目,结构指导的免疫原设计及广谱保护机制研究, 骨干;

8. 国家自然科学基金, 联合基金项目, U1705283, 基于结构的人乳头瘤病毒型别交叉疫苗的分子设计和免疫机制研究, 骨干;

9. 国家科技重大专项,新药创制项目,重组人乳头瘤病毒16/18型双价疫苗的III期临床研究和产业化,参与;

 

上一条:李智海

下一条:胡乃夫

国科大杭州高等研究院药物科学与技术学院 

电话:0571-86080393 

邮箱:yxy@ucas.ac.cn

国科大杭高院药学院